Document Detail


Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
MedLine Citation:
PMID:  23283649     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m(2) on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6-44.8 months), progression-free survival was 8.1 months (range 2.3-33.2 months), and time to treatment failure was 8.4 months (range 2.3-33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.
Authors:
Lorenzo Livi; Pierluigi Bonomo; Icro Meattini; Gabriele Simontacchi; Daniela Greto; Isacco Desideri; Fiammetta Meacci; Vieri Scotti; Sara Cecchini; Jacopo Nori; Luis Jose Sanchez; Lorenzo Orzalesi; Fabiola Paiar; Gianpaolo Biti
Related Documents :
17383529 - Use of an oncolytic virus secreting gm-csf as combined oncolytic and immunotherapy for ...
21177119 - Nasopharyngeal cancer (npc) around the mediterranean area: standard of care.
17128529 - Granulocytic growth factors and cancer-related neutropenia: limited effects.
23418909 - Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem...
7707109 - Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell r...
800969 - A patient with so-called primary reticulum cell sarcoma of the brain with 6.5 years' su...
23857399 - A phase ii study of the histone deacetylase inhibitor panobinostat (lbh589) in pretreat...
11757339 - Recurrent thymic carcinoid tumor in the pleural cavity. 2 cases of long-term survivors.
785199 - The use of oral bcg in the treatment or metastatic malignant melanoma.
Publication Detail:
Type:  Journal Article     Date:  2013-01-03
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  434     Citation Subset:  IM    
Affiliation:
Radiotherapy Unit, IFCA, University of Florence, Via di Barbano 2/A, 50129, Florence, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of ...
Next Document:  On Ethics and the Earthquake Resistant Interior Design of Buildings.